Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 10/20 | 0.46 |
| ▸ | LPAR2 | Q9HBW0 | 6/20 | 0.46 |
| ▸ | LPAR1 | Q92633 | 6/20 | 0.46 |
| ▸ | FDPS | P14324 | 2/20 | 0.34 |
| ▸ | MVD | P53602 | 1/20 | 0.33 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3429339 | 0.89 | LPAR3 (0.47) | LPAR3LPAR2LPAR1FDPSLPAR5 | |
| SCHEMBL13400437 | 0.85 | LPAR3 (0.55) | LPAR3LPAR2LPAR1FDPSLPAR5 | |
| SCHEMBL3429332 | 0.85 | LPAR3 (0.46) | LPAR3LPAR2LPAR1FDPSMVD | |
| SCHEMBL3429342 | 0.82 | LPAR3 (0.47) | LPAR3LPAR2LPAR1FDPSLPAR5 | |
| SCHEMBL3430182 | 0.82 | LPAR3 (0.52) | LPAR3LPAR2LPAR1FDPSLPAR5 | |
| SCHEMBL946310 | 0.82 | LPAR3 (0.44) | LPAR3LPAR2LPAR1FDPSMVD | |
| SCHEMBL28355254 | 0.81 | LPAR3 (0.59) | LPAR3LPAR2LPAR1FDPSLPAR5 | |
| SCHEMBL9879477 | 0.80 | LPAR3 (0.43) | LPAR3LPAR2LPAR1FDPSMVD | |
| SCHEMBL2349790 | 0.80 | LPAR3 (0.43) | LPAR3LPAR2LPAR1MVD | |
| SCHEMBL14278699 | 0.78 | LPAR3 (0.43) | LPAR3LPAR2LPAR1FDPSLPAR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691867-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2010-04-06 | — | — | US | disclosed |
| EP-1613619-B1 | QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-03-26 | — | — | EP | disclosed |
| US-20060270692-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | US | disclosed |
| EP-1613619-A1 | QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER | AstraZeneca AB (SE) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004094410-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270692-A1 | Chemical compounds | CCNI, MKI67, TP53 | LPAR3 3825/4885LPAR2 4113/4885LPAR1 3837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.